ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

FGEN FibroGen Inc

0.3518
-0.0131 (-3.59%)
11 Dec 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
FibroGen Inc NASDAQ:FGEN NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.0131 -3.59% 0.3518 0.3518 0.3536 0.38 0.35 0.37 503,872 23:15:21

FibroGen to Report Third Quarter 2024 Financial Results

04/11/2024 9:05pm

GlobeNewswire Inc.


FibroGen (NASDAQ:FGEN)
Historical Stock Chart


From Oct 2024 to Dec 2024

Click Here for more FibroGen Charts.

FibroGen, Inc. (NASDAQ: FGEN) will announce third quarter 2024 financial results on Tuesday, November 12 after the market close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance.

Conference Call and Webcast Toll-free: 1-877-300-8521International investors: 1-412-317-6026Webcast: Click here

To access the call, participants should dial the applicable telephone number above at least 5 minutes prior to the start of the call. A replay of the webcast will also be available for a limited time on the “Events and Presentation” page under the Investors section on the FibroGen website.

About FibroGen  FibroGen, Inc. is a biopharmaceutical company focused on accelerating the development of novel therapies at the frontiers of cancer biology. Roxadustat (爱瑞卓®, EVRENZO™) is currently approved in China, Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. Roxadustat is in clinical development for chemotherapy-induced anemia (CIA) and a Supplemental New Drug Application (sNDA) has been accepted for review by the China Health Authority. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46 is in development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of an associated CD46-targeted PET biomarker, FG-3180. In addition, FibroGen has expanded its research and development portfolio to include two immuno-oncology product candidates for the treatment of solid tumors. For more information, please visit www.fibrogen.com.

For Investor Inquiries:David DeLucia, CFAVice President of Corporate FP&A / Investor RelationsInvestorRelations@fibrogen.com

1 Year FibroGen Chart

1 Year FibroGen Chart

1 Month FibroGen Chart

1 Month FibroGen Chart

Your Recent History

Delayed Upgrade Clock